Home » Topics » BioWorld Science, Conferences

BioWorld Science, Conferences
RSS

Clinical data reported for boceprevir plus PegIntron/ribavirin in HCV

Nov. 18, 2009

Data from phase III trials support safety and efficacy of tenofovir DF in CHB patients

Nov. 18, 2009

SB-939 shows favorable PK, PD and safety in phase I trial in advanced solid tumors

Nov. 17, 2009

IMO-2125 shows promising anti-HCV activity in preclinical evaluation

Nov. 17, 2009

Taribavirin has anemia benefits versus ribavirin in HCV patients

Nov. 17, 2009

Vicriviroc exhibits long-term safety in phase II HIV trials, phase III trials under way

Nov. 17, 2009

PEG-Interferon lambda effective in HCV genotype 1 relapsed patients

Nov. 17, 2009

Entecavir exhibits superior antiviral activity to adefovir in CHB patients

Nov. 17, 2009

Promising preclinical and phase IIa data on S/GSK-1349572 disclosed

Nov. 16, 2009

Phase I/II data show VIR-576 to be safe and effective in HIV

Nov. 16, 2009

Popular Stories

Today's news in brief
BioWorld
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
VST Bio’s VB-001 is neuroprotector after stroke
BioWorld Science
At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...